embryo-screening
(2)
Nucleus Genomics
Nucleus Genomics is a New York-based consumer genomics company that sells a $399 at-home, clinical-grade whole-genome sequencing kit and a software platform that turns a person's full DNA sequence into readable reports on disease risk, carrier status, traits, and longevity. Founded in 2021 by Thiel Fellow Kian Sadeghi, Nucleus pairs whole-genome data with polygenic risk scores and lifestyle inputs to estimate risk for common, complex conditions. In 2025 it expanded into reproductive products - carrier screening, partner DNA alignment, and a controversial embryo-ranking tool, Nucleus Embryo - that put the company at the center of a public debate over the science and ethics of genetic selection.
Orchid
Orchid is a reproductive genetics company offering the first commercially available whole-genome sequencing test for IVF embryos. Founded by Noor Siddiqui in 2019, Orchid reads more than 99% of an embryo's genome before implantation and screens for over 1,200 monogenic conditions, chromosomal abnormalities, de novo mutations, and polygenic disease risk - so prospective parents can make informed choices before pregnancy begins.